诚达药业(301201) - 2025 Q4 - 年度业绩预告

Financial Performance - The company expects a net loss of between RMB 11 million and RMB 18 million for the fiscal year 2025, compared to a loss of RMB 28.1 million in the same period last year[5]. - The net loss after deducting non-recurring gains and losses is projected to be between RMB 27.5 million and RMB 34.5 million, an improvement from a loss of RMB 57.67 million in the previous year[5]. - Basic earnings per share are estimated to be between -0.0726 yuan and -0.1188 yuan, compared to -0.1849 yuan per share last year[5]. - The company is in a loss position but has narrowed the loss margin compared to the same period last year[8]. Revenue and Expenses - The company has implemented effective sales strategies and market development efforts, leading to a steady increase in operating revenue[8]. - The increase in fixed asset scale due to completed investment projects has resulted in higher depreciation and amortization expenses[8]. - Non-recurring gains and losses are expected to impact net profit by approximately RMB 16.5 million, mainly from government subsidies and cash management investment income[8]. Research and Development - The wholly-owned subsidiary, Shanghai Jiuqian Cheng Bio-pharmaceutical Co., Ltd., is still in the R&D phase for innovative drugs and has not yet generated revenue[8]. Financial Reporting and Investor Guidance - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the 2025 annual report[9]. - Investors are advised to make cautious decisions and be aware of investment risks[9].